NGL Fine-Chem Limited (NSE:NGLFINE)
2,801.00
+299.10 (11.95%)
May 22, 2026, 3:29 PM IST
NGL Fine-Chem Revenue
In the fiscal year ending March 31, 2026, NGL Fine-Chem had annual revenue of 5.16B INR with 40.03% growth. NGL Fine-Chem had revenue of 1.52B in the quarter ending March 31, 2026, with 59.81% growth.
Revenue
5.16B
Revenue Growth
+40.03%
P/S Ratio
3.32
Revenue / Employee
9.92M
Employees
520
Market Cap
17.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 5.16B | 1.47B | 40.03% |
| Mar 31, 2025 | 3.68B | 295.68M | 8.73% |
| Mar 31, 2024 | 3.39B | 606.08M | 21.79% |
| Mar 31, 2023 | 2.78B | -394.22M | -12.42% |
| Mar 31, 2022 | 3.18B | 595.28M | 23.08% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 584.62B |
| Cipla | 277.12B |
| Apollo Hospitals Enterprise | 252.29B |
| Divi's Laboratories | 103.14B |
| Indoco Remedies | 18.45B |
| Shalby | 11.19B |
| Windlas Biotech | 9.22B |
| Krsnaa Diagnostics | 7.66B |
NGL Fine-Chem News
- 6 months ago - NGL Fine-Chem Ltd (BOM:524774) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 6 months ago - Q2 2026 Ngl Fine Chem Ltd Earnings Call Transcript - GuruFocus
- 1 year ago - NGL Fine-Chem Ltd (BOM:524774) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... - GuruFocus
- 1 year ago - Q2 2025 Ngl Fine Chem Ltd Earnings Call Transcript - GuruFocus